Spain· ES:1251917002
LYNOZYFIC 200 MG CONCENTRADO PARA SOLUCION PARA PERFUSION
A medicinal product containing linvoseltamab, registered in Spain by Regeneron Ireland Designated Activity Company.
Checked against AEMPS CIMA (Spain) on
Informational only — not a medical device.
The record
At a glance
AEMPS CIMA (Spain)- Active substance
- linvoseltamab
- Manufacturer
- Regeneron Ireland Designated Activity Company
- Country
- Spain (ES)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- AEMPS CIMA (Spain)
- Last checked
- June 3, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Linvoseltamab in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesLYNOZYFICRegeneron Pharmaceuticals, Inc.
- CzechiaLYNOZYFICRegeneron Ireland Designated Activity Company, Dublin
- BelgiumLynozyfic 200 mgRegeneron Ireland Designated Activity Company (DAC)
- FinlandLYNOZYFICRegeneron Ireland Designated Activity Company (DAC)
- IrelandLYNOZYFIC 200 mg concentrate for solution for infusionRegeneron Ireland Designated Activity Company
- IcelandLynozyficRegeneron Ireland Designated Activity Company
- NetherlandsLYNOZYFIC 200 mg concentraat voor oplossing voor infusieRegeneron Ireland Designated Activity Company
- PolandLynozyficRegeneron Ireland DAC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Lynozyfic
- Liechtenstein · Lynozyfic
- Norway · Lynozyfic
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e8b8ac13-137c-476d-9e4d-b44912c6f851 GET /v1/drugs/e8b8ac13-137c-476d-9e4d-b44912c6f851?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cpresc": "Uso Hospitalario",
"estado": "{\"aut\":1765879386000}",
"nregistro": "1251917002",
"substance": "linvoseltamab"
}See everything about linvoseltamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.